Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival

Bone Marrow Transplantation volume 35, pages 985–990 (2005)Cite this article

Summary:

In this retrospective single-centre study, 96 consecutive myeloma patients were treated with melphalan 200 mg/m2 with blood stem cell support as first-line therapy. Their mean age was 55 (38–65) years. The impact of renal function on stem cell collection yield, engraftment, transplantation-related toxicity and overall survival was studied. Glomerular filtration rate (GFR) was evaluated by iohexol clearance, a median 32 days before high-dose administration. Chronic renal failure (GFR <60 ml/min) was present in 19 patients, with severe failure (GFR <30 ml/min) in five patients, including one patient on haemodialysis. No relationship between GFR and stem cell collection yield or engraftment was observed, nor was the incidence of neutropenic fever or infectious complications related to GFR. Patients with subnormal renal function, however, were more often affected by severe mucositis. In addition, the two patients with severe GI bleeding, the two pneumonia patients who needed ventilator support and the only therapy-related death were noted in the five patients with severe renal failure. Lower iohexol clearance at the time of high-dose administration was found to have a poor impact on survival. A reduction of melphalan dose in patients with severe renal failure, here defined as iohexol clerarance <30 ml/min, is suggested.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91–97.

    Article  CAS  PubMed  Google Scholar 

  2. Fermand JP, Ravaud P, Chevret S et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multi-center sequential randomized clinical trial. Blood 1998; 92: 3131–3136.

    CAS  PubMed  Google Scholar 

  3. Lenhoff S, Hjorth M, Holmberg E et al. Impact on survival of high-dose therapy with autologous stem cell support in patients younger than 60 years with newly diagnosed multiple myeloma: a population-based study. Blood 2000; 95: 7–11.

    CAS  PubMed  Google Scholar 

  4. Alexanian R, Barlogie B, Dixon D . Renal failure in multiple myeloma: pathogenesis and prognostic implications. Arch Intern Med 1990; 150: 1693–1695.

    Article  CAS  PubMed  Google Scholar 

  5. Knudsen LM, Hippe E, Hjorth M et al. Renal function in newly diagnosed multiple myeloma. Eur J Haematol 1994; 53: 207–212.

    Article  CAS  PubMed  Google Scholar 

  6. Iggo N, Palmer ABD, Severn A et al. Chronic dialysis in patients with multiple myeloma and renal failure: a worthwhile treatment. Q J Med 1989; 270: 903–910.

    Google Scholar 

  7. Innes A, Cuthbert RJ, Russell NH et al. Intensive treatment of renal failure in patients with multiple myeloma. Clin Lab Haematol 1994; 16: 149–156.

    Article  CAS  PubMed  Google Scholar 

  8. Johnson WJ, Kyle RA, Pineda AA et al. Treatment of renal failure associated with multiple myeloma. Plasmapheresis, hemodialysis and chemotherapy. Arch Intern Med 1990; 150: 863–869.

    Article  CAS  PubMed  Google Scholar 

  9. Knudsen LM, Hjorth M, Hippe E . Renal failure in multiple myeloma: reversibility and impact on the prognosis. Eur J Haematol 2000; 65: 175–181.

    Article  CAS  PubMed  Google Scholar 

  10. Torra R, Bladé J, Cases A, Lopez-Pedret J . Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases. Br J Haematol 1995; 91: 854–859.

    Article  CAS  PubMed  Google Scholar 

  11. Badros A, Barlogie B, Siegel E et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol 2001; 114: 822–829.

    Article  CAS  PubMed  Google Scholar 

  12. Ballester OF, Tummala R, Janssen WE et al. High-dose chemotherapy and autologous peripheral blood stem cell transplantation in patients with multiple myeloma and renal insufficiency. Bone Marrow Transplant 1997; 20: 653–656.

    Article  CAS  PubMed  Google Scholar 

  13. San Miguel JF, Lahuerta JJ, Garcia-Sanz R et al. Are myeloma patients with renal failure candidates for autologous stem cell transplantation? Hematol J 2000; 1: 28–36.

    Article  CAS  PubMed  Google Scholar 

  14. Sirohi B, Powles R, Kulkarni S et al. Glomerular filtration rate prior to high-dose melphalan 200 mg/m2 as a surrogate marker of outcome in patients with myeloma. Br J Cancer 2001; 85: 325–332.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Tosi P, Zamagni E, Ronconi S et al. Safety of autologous hematopoietic stem cell transplantation in patients with multiple myeloma and chronic renal failure. Leukemia 2000; 14: 1310–1313.

    Article  CAS  PubMed  Google Scholar 

  16. Tricot G, Alberts DS, Johnson C et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res 1996; 2: 947–952.

    CAS  PubMed  Google Scholar 

  17. Lee C-K, Zangari M, Barlogie B et al. Myeloma. Dialysis-dependent renal failure in patients with myeloma can be reversed by high-dose myeloablative therapy and autotransplant. Bone Marrow Transplant 2004; 33: 823–828.

    Article  CAS  PubMed  Google Scholar 

  18. Child A, Morgan G, Davies F et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875–1883.

    Article  CAS  PubMed  Google Scholar 

  19. Lenhoff S, Hjorth M, Westin J et al. Impact of age on survival after high-dose therapy with autologous stem cell support in newly diagnosed multiple myeloma: a population-based study. (submitted for publication).

  20. Cockcroft DW, Gault MH . Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.

    Article  CAS  PubMed  Google Scholar 

  21. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002; 39 (Suppl. 1): S1–S266.

  22. Knudsen LM, Nielsen B, Gimsing P, Geisler C . Autolgous stem cell transplantation in multiple myeloma with renal failure. Blood 2003; 102: 985a (abstract 3667).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, Uppsala University Hospital, Sweden

    K Carlson

Authors
  1. K Carlson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K Carlson.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Carlson, K. Melphalan 200 mg/m2 with blood stem cell support as first-line myeloma therapy: impact of glomerular filtration rate on engraftment, transplantation-related toxicity and survival. Bone Marrow Transplant 35, 985–990 (2005). https://doi.org/10.1038/sj.bmt.1704948

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1704948

Keywords

This article is cited by

Search

Advanced search

Quick links